186 related articles for article (PubMed ID: 2807549)
1. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.
Szu SC; Li XR; Schneerson R; Vickers JH; Bryla D; Robbins JB
Infect Immun; 1989 Dec; 57(12):3823-7. PubMed ID: 2807549
[TBL] [Abstract][Full Text] [Related]
2. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
[TBL] [Abstract][Full Text] [Related]
3. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
Szu SC; Taylor DN; Trofa AC; Clements JD; Shiloach J; Sadoff JC; Bryla DA; Robbins JB
Infect Immun; 1994 Oct; 62(10):4440-4. PubMed ID: 7927707
[TBL] [Abstract][Full Text] [Related]
4. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
5. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.
Szu SC; Bystricky S; Hinojosa-Ahumada M; Egan W; Robbins JB
Infect Immun; 1994 Dec; 62(12):5545-9. PubMed ID: 7960137
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
[TBL] [Abstract][Full Text] [Related]
8. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates.
Schneerson R; Robbins JB; Chu C; Sutton A; Vann W; Vickers JC; London WT; Curfman B; Hardegree MC; Shiloach J
Infect Immun; 1984 Sep; 45(3):582-91. PubMed ID: 6332076
[TBL] [Abstract][Full Text] [Related]
9. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.
Kossaczka Z; Bystricky S; Bryla DA; Shiloach J; Robbins JB; Szu SC
Infect Immun; 1997 Jun; 65(6):2088-93. PubMed ID: 9169736
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid.
Bergquist C; Lagergård T; Holmgren J
APMIS; 1998 Aug; 106(8):800-6. PubMed ID: 9744766
[TBL] [Abstract][Full Text] [Related]
12. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
An SJ; Yoon YK; Kothari S; Kothari N; Kim JA; Lee E; Kim DR; Park TH; Smith GW; Carbis R
Vaccine; 2011 Oct; 29(44):7618-23. PubMed ID: 21843575
[TBL] [Abstract][Full Text] [Related]
13. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
Robbins JD; Robbins JB
J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
[TBL] [Abstract][Full Text] [Related]
14. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
15. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
[TBL] [Abstract][Full Text] [Related]
16. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
Meena J; Kumar R; Singh M; Ahmed A; Panda AK
Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
[TBL] [Abstract][Full Text] [Related]
17. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.
Tritama E; Riani C; Rudiansyah I; Hidayat A; Kharisnaeni SA; Retnoningrum DS
Hum Vaccin Immunother; 2018 Jun; 14(6):1524-1529. PubMed ID: 29359991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
